Shanghai Junshi Biomedical Technology filed a patent for using anti-PD-1 antibodies to prevent or treat malignant cancer, specifically nasopharyngeal carcinoma. The patent also covers using a combination of anti-PD-1 antibodies and gemcitabine-cisplatin for the same purpose, along with a method to predict treatment effectiveness. GlobalData’s report on Shanghai Junshi Biomedical Technology gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Shanghai Junshi Biomedical Technology, Personalized cancer vaccines was a key innovation area identified from patents. Shanghai Junshi Biomedical Technology's grant share as of January 2024 was 19%. Grant share is based on the ratio of number of grants to total number of patents.
Anti-pd-1 antibody for treating nasopharyngeal carcinoma
See Also:
A recently filed patent (Publication Number: US20230365691A1) outlines a method for preventing or treating malignant cancer, specifically nasopharyngeal carcinoma, by administering an anti-PD-1 antibody alone or in combination with gemcitabine-cisplatin. The method targets recurrent or metastatic nasopharyngeal carcinoma, with a focus on cases exhibiting PD-L1 expression levels above certain thresholds. The patent also details specific amino acid sequences for the anti-PD-1 antibody or its fragments, along with recommended dosages and administration frequencies for optimal therapeutic effect.
Furthermore, the patent describes a pharmaceutical composition comprising the anti-PD-1 antibody, gemcitabine, and cisplatin for treating nasopharyngeal carcinoma. It also introduces a method for predicting the therapeutic effect of the anti-PD-1 antibody based on genetic markers related to the cancer, such as gene mutations or EBV DNA levels. The method emphasizes personalized treatment approaches based on individual genetic profiles and outlines dosing regimens for both standalone and combination therapies. Overall, the patent provides a comprehensive framework for utilizing anti-PD-1 antibodies in conjunction with chemotherapy for the effective management of nasopharyngeal carcinoma.
To know more about GlobalData’s detailed insights on Shanghai Junshi Biomedical Technology, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
